Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
107M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
69M
-
Shares change
-
-663K
-
Total reported value, excl. options
-
$376M
-
Value change
-
-$4.07M
-
Put/Call ratio
-
0.2
-
Number of buys
-
51
-
Number of sells
-
-38
-
Price
-
$5.46
Significant Holders of MAXCYTE, INC. - Common Stock, par value $0.01 per share (MXCT) as of Q4 2022
113 filings reported holding MXCT - MAXCYTE, INC. - Common Stock, par value $0.01 per share as of Q4 2022.
MAXCYTE, INC. - Common Stock, par value $0.01 per share (MXCT) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69M shares
of 107M outstanding shares and own 64.53% of the company stock.
Largest 10 shareholders include Casdin Capital, LLC (9.51M shares), BlackRock Inc. (6.82M shares), Vitruvian Partners LLP (5.04M shares), VANGUARD GROUP INC (4.85M shares), Blue Water Life Science Advisors, LP (3.23M shares), Holocene Advisors, LP (2.74M shares), ArrowMark Colorado Holdings LLC (2.26M shares), BAMCO INC /NY/ (2.18M shares), CITADEL ADVISORS LLC (2.13M shares), and MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (1.97M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.